From: An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Parameter | Data | Source |
---|---|---|
Incidence, among hypertension patients (age dependent) | ||
 Myocardial infarction | 0%–0.82% | NHIS database 2019–2020 |
 Stroke | 2.47%–6.04% | |
 Heart failure | 2.47%–12.75% | |
 Hypotension | 0%–0.83% | |
 Syncope | 0%–2.01% | |
 Bradycardia | 0%–1.32% | |
 Electrolyte abnormality | 2.01%–3.31% | |
 Injurious fall | 34.23%–37.86% | |
 Acute renal failure | 0.41%–4.70% | |
Mortality, among hypertension patients (age dependent) | ||
 Hypertension | 0.04%–0.53% | NHIS database 2019–2020 |
 Myocardial infarction | 0% | |
 Stroke | 0%–0.67% | |
 Heart failure | 0%–2.01% | |
 Hypotension | 0%–0.41% | |
 Syncope | 0%–0.28% | |
 Bradycardia | 0% | |
 Electrolyte abnormality | 0%–0.26% | |
 Injurious fall | 0.41%–1.34% | |
 Acute renal failure | 0%–2.01% | |
Hazard ratio (Intensive vs. Standard treatment) | HR (95% CI) | Â |
 Disease events | 0.94 (0.62–1.44) |  |
  Myocardial infarction | 1.35 (0.60–3.08) | Cheung, et al [7] 2017 |
  Stroke | 0.99 (0.57–1.70) | |
  Heart failure | 0.72 (0.47–1.10) | |
  Hypotension | 1.34 (0.88–2.04) | |
  Syncope | 1.28 (0.86–1.92) | |
  Bradycardia | 0.92 (0.59–1.44) | |
  Electrolyte abnormality | 1.35 (0.94–1.94) | |
  Injurious fall | 0.90 (0.71–1.15) | |
  Acute renal failure | 1.46 (1.10–1.95) | |
  Cardiovascular disease death | 0.57 (0.31–1.02) | |
  Non-cardiovascular disease death | 0.72 (0.53–0.99) | |
Costs (per person, per 1-year, US$, age dependent) | Â | Â |
 Hypertension | 386.4–1,943.3 | NHIS database 2019–2020 |
 Myocardial infarction | 159.8–26,696.9 | |
 Stroke | 2,406.1–14,109.8 | |
 Heart failure | 4,508.8–6,371.5 | |
 Hypotension | 67.0–7,930.4 | |
 Syncope | 494.6–2,882.2 | |
 Bradycardia | 365.0–3,643.9 | |
 Electrolyte abnormality | 643.6–5,511.5 | |
 Injurious fall | 4,157.2–14,087.9 | |
 Acute renal failure | 5,418.7–27,676.9 | |
Utility (quality-adjusted life year) | ||
 Hypertension | 1.00 | Sullivan et al [11] 2006 |
 Stroke | 0.65 | |
 Myocardial infarction | 0.70 | |
 Heart failure | 0.64 | |
 Serious adverse events | 0.60 |